Streamex Corp. · NASDAQ:STEX
Streamex — BioSig Technologies — Winter 2021 Investor Conference
15 slides from Streamex's conference presentation, Jan 13, 2021
Slide 1: Winter 2021 Investor Conference
BieSin, . “teeee: technologies auc Winter 2021 Investor Conference. , January 13" - 14th, 2021 ° NASDAQ: BSGM
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements including statements that address activities, events or developments that BioSig expects, believes or anticipates will or may occur in the future, such as predictions of financial performance, approvals and launches by BioSig of new pr
Slide 3: Who We Are
Who We Are - NASDAQ: BSGM Er SEE MORE, CLEARLY ¢ EP Tech Market 13.5% CAGR * Global EP Market Expected to be $12.2 Billion by 2026* ¢ 31 Patents Issued ¢ First Customer is #1 Center by Volume in U.S. ¢ Razor & Blade Business Model ¢ FDA Approved ¢ Unblinding of clinical data in 2021 et SYMBOL: BSGM
Slide 4: PURE EP Developed Through Collaboration with Leading Centers
PURE EP™ Developed Through Collaboration with Leading Centers Relationships at leading, high-volume centers create traction for PURE EP™ in the market Concept developed Proof of concept Prototype test Initial pre-clinical First pre-clinical Advanced research with Texas Cardiac test completed with UC
Slide 5: Market Opportunity - PURE EP
Market Opportunity - PURE EP ™ Complex Cardiac Ablation: ous: 13.5% Growth Rate | 3,495 3,915 EP labs EP labs Total Global Addressable Market $2.0 Billion SYMBOL: BSGM.
Slide 6: EP During COVID-19
EP During COVID-19 From 2019 to 2020 ablations and LAAO (DRG 274) had a reimbursement rate increase of 8.8% Delaying procedure increases stroke risk and worsens outcomes + CV surgery and invasive cardiology have the highest net annual revenue compared to all other service lines CMS Reimbursement Cha
Slide 7: PURE EP System - Customer Sites
PURE EP™ System - Customer (ail evens Hospital of the . Ze P| ; University of Pennsylvania tA “y \ th 14 PURE EP Texas Cardiac Arrhythmia Institute BioSig sYMBol:esem | 7 ‘chnaloges
Slide 8: Challenges in EP For All Procedures
Challenges in EP For All Procedures Signal Quality Physicians Can’t Fix What They Can’t See 81% of palcers rated signal quality as “Critical” Success Rate 20 - 40% of ablations are unsuccessful PURE EP Control p jOSIg: o=evee mono sy20tro SYMBOL: BSGM.
Slide 9: Expanded Product Adoption, Experience, and a Growing Database
Expanded Product Adoption, Experience, and a Growing Database # PURE EP Procedures by Account # Physician Users TCAI (TX) 228 TCAL 1 Diagnosis Diagnosis Mayo JAX (FL) o1 Mayo Persistent AF Atypical Flutter Penn (PA) Hen MGH (MA) Deborah Deborah (NJ) AVNRT ER ECS Overland Park verland Park (KS) v ypi
Slide 10: Our Recent PURE EP Study - ESC 2020
Our Recent PURE EP™ Study - ESC 2020 PURE EP ¢ Ablinded, independent analysis confirmed that the PURE EP™ system's signals are preferred to conventional sources + In 35.5% of samples, the reviewers selected PURE EP™ data because "more signal components were visible” « PURE EP™ System produces reliab
Slide 11: Physician Testimonies
Physician Testimonies “The PURE EP System does provide innovative design with greater resolution and greater bandwidth, which should allow for safer and more efficacious ablations in the future.” - K. Venkatachalam, M.D., Cardiac Electrophysiologist, Mayo Clinic oe | “The quality of the recording th
Slide 12: Commercialization - Regions and Centers of Excellence
Commercialization - Regions and Centers of Excellence Florida 120 EP Programs 240 Labs Texas 220 EP Programs 440 Labs Northeast 175 EP Programs 400 Labs Revenue Potential $286 Million symgol: ssam | a2
Slide 13: Business Model
Business Model Modules Service Agreements Er" RE, CLEARLY BioSigé o%-or:mnaneer cei caphsie Dieta symeou:asem | a3 BION asses saconmesom
Slide 14: Value Drivers
Value Drivers * Raised $41 million in 2020 * $32 million in cash on the balance sheet and no debt « Achieved first commercial contract 4Q20 * Expect to triple the customer base in 2021 * CE mark approval / EU entry Q4 2021 * Sequential revenue growth in 2021 yf Nasdaq: BSGM uncer SYMBOL: BSGM | 44
Slide 15: Management Team
Management Team Kenneth L. Londoner, MBA Founder, Chairman, CEO, Director J &W Seligman & Co.; Endicott Management Partners Natasha Drapeau Executive Vieo President 1G Group Pe Todd Wiltshire Senior Vice President, Corporate Development Fidelity Investments John Kowalski Vice President, Sales Biosen
BioSig Technologies — Winter 2021 Investor Conference on 6ix